20 January 2020 in Scandinavian Journal of Work, Environment & Health
EFEsben Meulengracht Flachs
Esben Meulengracht Flachs
Objective Albeit a pivotal risk for the development of hand eczema (HE), the exposure–response relationship between wet work and HE remains to be further investigated. Knowledge on exposure–response is important regarding preventive measures, medico-legal regulations and job-counseling. Recently, a job-exposure matrix (JEM) for wet work was developed, providing information on the likelihood of wet work. By combining the JEM with data on HE we aimed to investigate the relationship between extent of wet work and HE. Methods This study is a case–referent study including patients registered in the National Database of Contact Allergy, Denmark, and comprises data on sex, age, atopic dermatitis, HE, face eczema and patch testing results. Patients with HE served as cases and patients with facial eczema served as referents. Information on profession was retrieved from the DOC*X database in accordance with the DISCO-88 classification system. A wet-work-specific JEM provides – for each profession – an estimate for (i) the likelihood of wet work lasting ≥2 hours/day and (ii) the average number of hours of wet work per day. Results After two hours of wet hands and glove wear, the odds ratio (OR) was 3.49 and 3.19, respectively, for females and 2.41 and 1.82, respectively, for males. Females had a higher risk of HE than males with probability of wet hands <75% (OR 2.34, 95% CI 2.12–2.58 compared to males 1.68, 95% CI 1.22–2.31) and regarding glove wear at all exposure levels. Conclusion Our data confirms a close association between wet work and HE. Exposure lasting less than the current definition of wet work (having wet hands for ≥2 hours per day) may be of importance.
14 December 2022 in Journal of the European Academy of Dermatology and Venereology
16 April 2019 in International Archives of Occupational and Environmental Health
EFEsben Meulengrath Flachs
JSJennifer Astrup Sørensen
29 January 2019 in Dermatologic Therapy
Real‐life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of psoriasis is lacking. We retrospectively analysed patient records from 69 patients with moderate to severe psoriasis treated at the department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark in the period March 1st 2015 to October 1st 2017 who were administratively switched from the anti‐TNF biologics infliximab (Remicade) and etanercept (Enbrel) to the biosimilars Remsima and Benepali, respectively. Approximately 25% of patients treated with infliximab and approximately 40% of patients treated with etanercept reported a worse effect after being switched from the original drug to its biosimilar. Quality of life was worse in approximately 30% after switching in both patient groups, respectively. The number of patients reporting adverse events increased in both groups.
16 November 2018 in International Archives of Occupational and Environmental Health
EFEsben Meulengrath Flachs
31 August 2020 in Dermatologic Therapy
CNChristoffer Valdemar Nissen
Christoffer Valdemar Nissen
+1
Click on the article title to read more.